Eli Lilly: I Admit Defeat As I Understated Its Growth Prospects (Upgrade)
Eli Lilly's valuation is a critical concern, but its robust execution has improved its ability to actualize its high-growth ...
Eli Lilly urges court to toss $183 mln Medicaid fraud judgment
Drugmaker Eli Lilly on Wednesday urged a federal appeals court to overturn a $183 million judgment against it in a case ...
Eli Lilly (NYSE:LLY) Gains FDA Approval for EBGLYSS, Expands Strategic Alliances for Market Growth
Eli Lilly(NYSE:LLY) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights ...
Ibj.com2d
Eli Lilly request records of people who took copies of its weight-loss drug
The letter is the latest sign that the battle between the brand-name drug manufacturers and the companies that make and sell ...
Eli Lilly’s new CFO is a 23-year company veteran—showing how pharma firms rely on a ‘deep bench of qualified talent’
Good morning. Eli Lilly and Company has promoted longtime executive Lucas Montarce to the role of CFO. The move is similar to ...
Beyond Mounjaro and Zepbound: 6 Other Drugs That Could Be Blockbusters for Eli Lilly
Lilly clearly has an abundance of growth drivers -- and the list includes more than Mounjaro, Zepbound, and the six drugs ...
USA Today4d
New eczema drug from Eli Lilly receives FDA approval for children and adults
On Friday, the U.S. Food and Drug Administration approved Eli Lilly's eczema drug for use in adults and children 12 and ...
ENDPOINTS NEWS1h
Why did Eli Lil­ly ask a pa­tient on a com­pound­ed GLP-1 drug for their med­ical in­for­ma­tion?
This week, a letter surfaced in which Eli Lilly asked for a patient to release medical information so it could contact her ...